CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Nivolumab regimen improves outcomes in resectable non-small cell

Revisiting neoadjuvant therapy in non-small-cell lung cancer - The

肺癌围术期研究CheckMate-77T报捷，欧狄沃用于可切除肺癌再证疗效医药

PharmaScroll on LinkedIn: Phase 3 Trial Shows Neoadjuvant

New data support perioperative nivolumab for NSCLC

Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and

CheckMate 77T

Giulio Draetta: Tremendously proud of Tina Cascone for her

Neoadjuvant, Adjuvant Nivolumab Improve EFS in Resectable NSCLC

Perioperative Nivolumab Improves EFS in NSCLC - Cancer Therapy Advisor

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer